Clinical trials · Virginia
Recurrent Ovarian Cancer clinical trials in Virginia
We’re tracking 34 recruiting recurrent ovarian cancer studies with a site in Virginia — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Virginia
- NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Fairfax, VirginiaAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Woodbridge, VirginiaAges 18–60 - NCT06276491RecruitingPhase 1
Safety study of an investigational drug for advanced cancer with the CLDN6 marker
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
Charlottesville, VirginiaAges 15 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Charlottesville, VirginiaAges 18 years+ - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Fairfax, VirginiaAges 18 years+ - NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Charlottesville, VirginiaAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Fairfax, VirginiaAges 18–130 - NCT05128825RecruitingPhase 2
Azenosertib for platinum-resistant ovarian cancer with cyclin e1
This trial tests a new pill called azenosertib (ZN-c3) for ovarian cancer that stopped responding to platinum chemotherapy. The drug targets tumors with high levels of the Cyclin E1 protein, and the goal is to see if it can shrink tumors or slow the cancer's growth.
Chesapeake, VirginiaAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
TUB-040 for advanced ovarian or lung cancer after standard treatments fail
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
Fairfax, VirginiaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Fairfax, VirginiaAges 18 years+
Where these studies are running in Virginia
Institutions with a site for the recruiting recurrent ovarian cancer studies listed above.
- University of Virginia · 2 studies
- Augusta Health
- Bon Secours Cancer Institute at Reynolds Crossing
- Bon Secours Memorial Regional Medical Center
- Bon Secours Richmond Community Hospital
- Bon Secours Saint Francis Medical Center
- Bon Secours St. Mary's Hospital
- Bon Secours Westchester Emergency Center
What taking part in a recurrent ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Recurrent Ovarian Cancer trials in other states
Common questions
- Are there recurrent ovarian cancer clinical trials in Virginia?
- Yes. We're currently tracking 34 recruiting recurrent ovarian cancer studies with a site in Virginia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a recurrent ovarian cancer study in Virginia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Virginia to take part?
- Not necessarily. These studies have a site in Virginia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a recurrent ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New recurrent ovarian cancer studies open in Virginia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.